HR Execs on the Move

Sun Pharma

www.sunpharma.com

 
Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Jonathan Moore
 Sr. Director, Talent Acquisition Profile
Suresh Rai
 Senior Vice President and Chief Human Resources Officer Profile
Colleen Neff
 Sr. Director, Human Resources Profile
Carri Kline
 Associate Director of Total Rewards and Performance Management Profile
Azadar Khan
 Senior GM-HR Profile

Similar Companies

Miller Pharmacy

Miller Pharmacy is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ultimed

Ultimed is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lafayette Drug Company,

Lafayette Drug Company, is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Redox Pharmaceutical

Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).